Market News AIOpen the app

DFTX stock news · Definium Therapeutics

Stories about Definium Therapeutics (DFTX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for DFTX

Follow Definium Therapeutics (DFTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DFTX
Free on the App Store and Google Play, or on the web.
  1. Nov 9, 2026, 7:37 PM ET · Results

    Definium Therapeutics Q3 2026 Earnings Call Transcript

    Good for DFTX

    Definium reported positive Phase 3 results in 3 studies, received 2 FDA Breakthrough Therapy designations, and plans an approval application in the first half of 2027. These advances support its outlook.

  2. Aug 12, 2026, 10:34 AM ET · Market

    Definium Therapeutics Claims Remarkable Effectiveness from Anxiety Trial 'Sets New Standards'.

    Good for DFTX

    Definium Therapeutics has reported unprecedented efficacy from its Phase 3 Voyage trial for DT120 ODT in treating generalized anxiety disorder, achieving significant improvements over placebo. This positive outcome is expected to boost investor confidence and potentially increase the company's stock value as it positions itself as a leader in mental health treatments.